NEW BRUNSWICK, Nj. – Johnson & Johnson is the latest U.S. drugmaker to announce a deal with the Trump Administration to lower drug costs for customers while sidestepping costly tariffs.
The New Jersey-based company also announced a new manufacturing site in Pennsylvania but didn’t offer specifics about where the facility will be.
Specifics of the deal with President Trump and his administration also were not disclosed. Johnson & Johnson said the agreement would “improve access to medicines and lower costs for millions of American patients,” while also giving the company’s pharmaceutical products an exemption from tariffs.
“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, in a news release.
Johnson & Johnson said it would participate in the government-run website TrumpRx.com, which the Trump administration said will provide consumers with “massive price reductions” when they purchase their medicines directly from the site. The company didn’t say which drugs it would offer on TrumpRx.
The website is expected to launch this month, but an exact date has not been provided. The site was not yet active as of Friday morning.
Since September, the White House has announced deals with 14 pharmaceutical companies, including Merck and Sanofi, to lower prescription drug prices.
Those drugmakers also will offer some of their products on TrumpRx.com, the White House said. For example, Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through the website; also, Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16, and list its insulin products at $35 per month’s supply.
While unveiling its agreement with the White House, Johnson & Johnson also announced two new U.S. manufacturing facilities: a next generation cell therapy manufacturing site in Pennsylvania and a drug product manufacturing facility in North Carolina.
69 News has reached out to the company for more information about the Pennsylvania facility but did not immediately hear back.
The new facilities are part of a previously announced $55 billion investment in U.S. manufacturing.